News
Media
Conferences
Publication
Job Board
CME/CE
Partners
Editorial
Resources
Subscribe

Spotlight -

Long-Acting Injectable Therapy in the Management of Adult Patients with Schizophrenia|

Major Depressive Disorder

|Videos|May 19, 2022

Current Trends in Suicide: APA Preview With the Chief Medical Officer of the AFSP

Author(s)Christine Yu Moutier, MD

Christine Yu Moutier, MD, is excited to see you at the APA Annual Meeting in New Orleans!

Christine Yu Moutier, MD, the Chief Medical Officer for the AFSP, is excited to be attending APA's Annual Meeting in New Orleans. What is she looking forward to? Find out here.

Be sure not to miss her talk, Current Trends in Suicide Research and Prevention, on Saturday May 21 at 4:00 PM - 5:30 PM CDT.

Dr Moutier is chief medical officer of the American Foundation for Suicide Prevention, New York, NY.

Newsletter

Receive trusted psychiatric news, expert analysis, and clinical insights — subscribe today to support your practice and your patients.

Related Content

Dronabinol for Agitation in Autism Spectrum Disorder: Research From the National Update on Behavioral Emergencies Conference

ByJessica Walters

December 22nd 2025

alzheimer disease trontinemab

Trontinemab Shows Promise for Treatment of Alzheimer Disease in New Data at CTAD

ByJessica Walters

December 12th 2025

semaglutide alzheimer

Data Fails to Show Significant Change in Cognition and Function With Oral Semaglutide for Early Alzheimer Disease

ByJessica Walters

December 8th 2025

Alzheimer disease

Favorable Profile Data On MK-2214 for Treatment of Alzheimer Disease

ByJessica Walters

December 5th 2025

XPro1595 Alzheimer disease inflammation

Data Presentation on XPro1595 for Alzheimer Disease With Inflammation at CTAD

ByJessica Walters

December 3rd 2025

Latest CME

Real Psychiatry 2026

In-Person + Virtual Event

Real Psychiatry 2026

January 23-24, 2026

Managing Negative Symptoms of Schizophrenia: Can Prescription Digital Therapeutics Make an Impact?

Managing Negative Symptoms of Schizophrenia: Can Prescription Digital Therapeutics Make an Impact?

Michael Asbach, DMSc, PA-C; Erin Crown, MHS, PA-C, Psych-CAQ

Optimizing Care for Patients With Tardive Dyskinesia

Optimizing Care for Patients With Tardive Dyskinesia

Amber Hoberg, MSN, APRN, PMHNP-BC; Erin Crown, PA-C, Psych-CAQ

Stabilize and Thrive: Prioritizing Patient Success Through Novel Therapeutic Management in Schizophrenia

Stabilize and Thrive: Prioritizing Patient Success Through Novel Therapeutic Management in Schizophrenia

Jonathan Meyer, MD; Jacob Hanaie, PharmD, APh, BCPP; Sanjai Rao, MD, DFAPA

Southern California Psychiatry Conference

In-Person Event

Southern California Psychiatry Conference

July 10-11, 2026

Live Expert Illustrations & Commentary™: Visualizing Novel Therapeutic Targets for Patients with Major Depressive Disorder

Live Expert Illustrations & Commentary™: Visualizing Novel Therapeutic Targets for Patients with Major Depressive Disorder

Jason Kellogg, MD; Gus Alva, MD, DFAPA; Melanie Barrett, MD; Yvette Elpidio, MSN, FNP-C

(CME Track) SoCal Psych 2025: Overcoming Barriers to Long-Acting Injectable Agents in Schizophrenia

(CME Track) SoCal Psych 2025: Overcoming Barriers to Long-Acting Injectable Agents in Schizophrenia

Gus Alva, MD, DFAPA; Ilan Melnick, MD

Jersey City Psychiatry

In-Person Event

Jersey City Psychiatry

October 2-3, 2026

Southern Florida Psychiatry Conference

In-Person Event

Southern Florida Psychiatry Conference

December 4-5, 2026

Clear Skin, Clear Mind: Integrating Mental Health into Psoriasis Care

Clear Skin, Clear Mind: Integrating Mental Health into Psoriasis Care

John Koo, MD; T.J. Chao, MPAS, PA-C

Expert Illustrations & Commentary: Visualizing the Role of Novel Muscarinic Agents in the Management of Schizophrenia

Expert Illustrations & Commentary: Visualizing the Role of Novel Muscarinic Agents in the Management of Schizophrenia

Ilan Melnick, MD; Linda Collado, MD, DABPN, FAPA; Maria Collado, MD, FAPA

Overcoming Barriers to Long-Acting Injectable Agents in Schizophrenia

Overcoming Barriers to Long-Acting Injectable Agents in Schizophrenia

Patricia Junquera, MD; Maria Collado, MD; Erin C. Crown, MHSPAS, PA-C, Psych-CAQ

Expert Illustrations & Commentary: Visualizing Novel Therapeutic Targets for Patients with Major Depressive Disorder

Expert Illustrations & Commentary: Visualizing Novel Therapeutic Targets for Patients with Major Depressive Disorder

Juan D. Oms, MD, FAPA; Linda Collado, MD, DABPN, FAPA; Ginger Shupe, MD

Live Expert Illustrations & Commentary™: Visualizing Novel Therapeutic Targets for Patients with Major Depressive Disorder

Live Expert Illustrations & Commentary™: Visualizing Novel Therapeutic Targets for Patients with Major Depressive Disorder

Jason Kellogg, MD; Gus Alva, MD, DFAPA; Melanie Barrett, MD; Yvette Elpidio, MSN, FNP-C

(Pharmacist Track) SoCal Psych 2025: Overcoming Barriers to Long-Acting Injectable Agents in Schizophrenia

(Pharmacist Track) SoCal Psych 2025: Overcoming Barriers to Long-Acting Injectable Agents in Schizophrenia

Gus Alva, MD, DFAPA; Ilan Melnick, MD

Trending on Psychiatric Times

FDA Approves ProlivRX: First Prescription, Physician-Directed, At-Home Brain Neuromodulation Therapy for MDD

What Makes It So Special? A Review of the Mechanisms of Action of Lamotrigine, Carbamazepine, and Valproic Acid and How They Differ From Other Antiepileptics

Anticholinergic Burden and Its Effect on Cognition in Psychosis

Progress Report: Second Interim Safety Review of Phase 3 Trial of LPCN 1154 in Postpartum Depression

In Memoriam: The Many Faces of Psychiatrists and Psychiatry